December 1, 2010
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Key result
Concomitant omeprazole use in patients on dual antiplatelet therapy after PCI was associated with a higher rate of major adverse cardiac and cerebrovascular events at 12 months (55.6% vs 20.0%; p=0.02).
Why the study?
Does concomitant omeprazole use increase inflammatory markers and adverse cardiovascular events in patients receiving dual antiplatelet therapy after PCI?
Population
38 patients undergoing percutaneous coronary intervention receiving dual antiplatelet therapy
Comparison
Omeprazole added to dual antiplatelet therapy vs Dual antiplatelet therapy without omeprazole
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
May warrant avoiding omeprazole with DAPT post-PCI; leaves open confounding versus causal interaction needing randomized confirmation.
Study Design
Type
Cohort (n=38)
Structured PICO
Does concomitant omeprazole use increase inflammatory markers and adverse cardiovascular events in patients receiving dual antiplatelet therapy after PCI?
P
Population
38 patients on dual antiplatelet therapy undergoing percutaneous coronary intervention, followed for 12 months.
E
Exposure
Omeprazole added to dual antiplatelet therapy
C
Comparator
Dual antiplatelet therapy without omeprazole
O
Outcome
Levels of interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-β1), and major adverse cardiac and cerebrovascular events (MACCE: composite of death, re-hospitalization for acute coronary syndromes, and stroke) at 12 monthscomposite
Main Result
Absolute Event Rate: 55.6% vs 20%
p-value: p=0.02
Concomitant omeprazole use in patients on clopidogrel after PCI is associated with increased inflammation (IL-6) and a significantly higher risk of major adverse cardiovascular events.
Cite This Study
Hudzik et al. (2010) conducted a cohort in Patients receiving dual antiplatelet therapy after percutaneous coronary intervention (n=38). Omeprazole vs. No omeprazole was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) at 12 months (p=0.02). Concomitant omeprazole use in patients on dual antiplatelet therapy after PCI was associated with a higher rate of major adverse cardiac and cerebrovascular events at 12 months (55.6% vs 20.0%; p=0.02).